AGYRAX 25 mg

Generic Drug Therapeutic Class: Neurology-Psychiatry
active ingredients: Meclozine
laboratory: Ucb Pharma SA

Indication

In adults:

Symptomatic treatment of the vertiginous crisis.

Prevention and treatment of motion sickness.

Dosage AGYRAX 25 mg scored tablet Box of 15

Vertiginous crisis :

1 to 3 tablets daily to be taken before meals.

Swallow without chewing with a little water or another soft drink.

Motion sickness :

The first dose should be made 1 hour before the trip: 1 to 4 tablets per day.

Pediatric population: There are no data in children and adolescents

Against indications

· Hypersensitivity to meclozine, any of the components of the product, or to any of the piperazine derivatives

· Hepatic impairment (see section Pharmacokinetic properties )

· Linked to the anticholinergic effect:

o Risk of glaucoma by closing the angle

o Risk of urinary retention related to urethroprostatic disorders.

Agyrax side effects

Adverse effects of AGYRAX are mainly related to its action on the central nervous system, its anticholinergic effects and the hypersensitivity reactions it can cause. They are listed below by organ class. The most common side effects that are considered to be the most common are drowsiness or sedation. Dryness of the mouth is a common side effect. Blurred vision, nausea and vomiting rarely occur.

Cardiac disorders: palpitations, tachycardia

Affections of the ear and labyrinth : tinnitus, vertigo

Eye disorders : diplopia, blurred vision

Gastrointestinal disorders : abdominal pain, constipation, diarrhea, dry mouth, nausea, vomiting

General disorders : tiredness, weakness

Immune system disorders : anaphylactic shock.

Investigations: weight gain

Metabolism and nutrition disorders : anorexia, increased appetite

Nervous system disorders : dizziness, headache, paresthesia, sedation, drowsiness, movement disorders (including Parkinson's syndrome)

Psychiatric disorders : anxiety, euphoric mood, excitability, hallucinations, insomnia, psychotic disorders, memory problems, disorientation, confusion and paranoia.

Renal and urinary disorders : dysuria, polyuria, urinary retention

Respiratory, thoracic and mediastinal disorders : dry throat, nasal dryness

Vascular disorders : hypotension

Skin and subcutaneous tissue disorders : rash, urticaria.

Reporting of suspected adverse reactions

The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Health professionals report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centers. www.ansm.sante.fr.